ImmunityBio (NASDAQ:IBRX) Price Target Increased to $25.00 by Analysts at Piper Sandler
ImmunityBio (NASDAQ:IBRX) had its price objective increased by Piper Sandler from $18.00 to $25.00 in a research report released on Wednesday, The Fly reports. The brokerage currently has an overweight rating on the stock.
Shares of NASDAQ:IBRX opened at $18.74 on Wednesday. ImmunityBio has a one year low of $2.83 and a one year high of $45.42.
ImmunityBio Company Profile
Further Reading: What is basic economics?
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.